BONE MEDICAL: ORAL PARATHYROID HORMONE EQUALS INJECTED
May 13th 2008 09:20
Monday May 12, 2008
Daily news on ASX-listed biotechnology companies
* ASX UP, BIOTECHS DOWN: HEARTWARE UP 20%; LIVING CELL DOWN 11%
* BONE MEDICAL: ORAL PARATHYROID HORMONE EQUALS INJECTED
* STARPHARMA’S US HERPES TRIAL SHOWS VIVAGEL SAFE, TOLERATED
* FDA APROVES NOVOGEN PHASE III CANCER TRIAL CHANGES
* HELICON LICENCES EUSA’S COLLAGEN ANTIBIOTIC DEVICE
* UNIVERSAL BIOSENSORS EXPECTS J&J MILESTONE PAYMENTS
* FERMISCAN TELLS ASX: PRICE SPIKE NOT A CONFIDENTIALTY BREACH
* MEDICAL THERAPIES PLACES $507k
* ATO RULES ON CHEMGENEX DEMERGER TAX OPTIONS
* ANZ SELLS NO BIOPROSPECT, SOLAGRAN OPES PRIME SHARES
THE MARKET
Thirteen of the Biotech Daily Top 40 stocks were up, 15 fell, 10 were unchanged and two were untraded.
Heartware was best, up 11 cents or 20.37 percent to 65 cents on small volumes, followed by Sunshine Heart up one cent or 13.33 percent to 8.5 cents and Benitec up 0.7 cents or 7.87 percent to 9.6 cents.
Living Cell led the falls down three cents or 10.71 percent to 25 cents followed by Proteome down one cent or 7.14 percent to 13 cents and Impedimed down five cents or 6.25 percent to 75 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BONE MEDICAL
Bone Medical says new data shows an increased level above baseline of oral parathyroid hormone in blood comparable to injectable parathyroid hormone and above placebo.
Bone said the results came from testing its oral parathyroid hormone Capthymone osteoporosis product in a second clinical trial conducted at Qpharm in Brisbane.
Bone has previously said that increases in plasma calcium were seen in subjects treated with Capthymone containing 400µg or 800µg of parathyroid hormone 1-34 fragment equivalent to those seen for Eli Lilly’s Forteo, comprising a dose of 20µg of parathyroid hormone 1-34 fragment injected subcutaneously (see Biotech Daily; February 1, 2008).
The increases in calcium demonstrated that parathyroid hormone was entering the bloodstream via the oral route and exerting a biological effect, Bone said.
Bone said the findings were backed up by further analyses, showing that increases above baseline of parathyroid hormone fragments can be seen in the bloodstream shortly after administration of Capthymone.
The increases seen are comparable to those measured for injectable parathyroid hormone 1-34, during Bone’s first clinical trial, while placebo levels in the same trial stayed close to baseline.
The company said Capthymone complemented Bone’s Capsitonin (oral calcitonin), which has had “encouraging results” in phase IIb clinical trials.
Calcitonin targets osteoclasts, preventing them from breaking bone down, while parathyroid hormone up-regulates osteoblasts, whose role is to build new bone.
Bone said Calcitonin was available as an injectable and nasally administered product and was indicated for early stages of osteoporosis, while injectable parathyroid hormone was used in the later stages of osteoporosis, when the condition could be severe.
Bone chairman Dr Roger New said the availability of oral forms of these drugs would be “very pleasing news for osteoporosis sufferers”.
“The drugs are natural hormones of the body and oral drug forms will markedly increase the numbers of patients who use them,” Dr New said.
Bone climbed four cents or 16.67 percent to 28 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 38 |
| Vote |
Add To: 
Subscribe to this blog
